0001209191-20-031054.txt : 20200520
0001209191-20-031054.hdr.sgml : 20200520
20200520194939
ACCESSION NUMBER: 0001209191-20-031054
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200518
FILED AS OF DATE: 20200520
DATE AS OF CHANGE: 20200520
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sharp Shalini
CENTRAL INDEX KEY: 0001377202
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36276
FILM NUMBER: 20899611
MAIL ADDRESS:
STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC.
STREET 2: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ultragenyx Pharmaceutical Inc.
CENTRAL INDEX KEY: 0001515673
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 272546083
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 415-483-8800
MAIL ADDRESS:
STREET 1: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-18
0
0001515673
Ultragenyx Pharmaceutical Inc.
RARE
0001377202
Sharp Shalini
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT
NOVATO
CA
94949
0
1
0
0
CFO & Executive Vice President
Common Stock
2020-05-18
4
M
0
19593
70.57
A
122929
D
Common Stock
2020-05-18
4
S
0
19593
73.34
D
103336
D
Common Stock
2020-05-18
4
S
0
2392
73.29
D
100944
D
Common Stock
2020-05-19
4
M
0
3221
48.43
A
104165
D
Common Stock
2020-05-19
4
S
0
3221
73.32
D
100944
D
Common Stock
2020-05-19
4
M
0
3907
70.57
A
104851
D
Common Stock
2020-05-19
4
S
0
3907
73.32
D
101556
D
Stock Option (Right to Buy)
70.57
2020-05-18
4
M
0
19593
0.00
D
2026-06-01
Common Stock
19593
4407
D
Stock Option (Right to Buy)
48.43
2020-05-19
4
M
0
3221
0.00
D
2028-03-01
Common Stock
3221
31779
D
Stock Option (Right to Buy)
70.57
2020-05-19
4
M
0
3907
0.00
D
2026-06-01
Common Stock
3907
500
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.04 to $73.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.01 to $73.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.05 to $73.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Includes 612 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2020.
1/4th of the option vested one year from June 1, 2016 and then 1/48th of the option vested and will vest monthly thereafter.
1/4th of the option vested one year from March 1, 2018 and then 1/48th of the option vested and will continue to vest monthly thereafter.
/s/ Karah Parschauer, attorney-in-fact
2020-05-20